Pilot Study of Fosamax in Spinal Cord Injury

• Status: Terminated
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Study is designed to evaluate the efficacy of oral fosamax in prevention on osteoporosis in acute spinal cord injury. Efficacy will be measured by a duel energy X-Ray absorptiometry (DEXA) scan every 6 months. Patients will complete 3 visits, screening, 6 months, 12 months and be required to take oral fosamax versus placebo weekly.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Rochester
• Treatments: Alendronate

Criteria

Inclusion Criteria:

• American Spinal Cord Injury Association (ASIA) A or American Spinal Cord Injury Association (ASIA) B Spinal Cord Injury

Exclusion Criteria:

• History of hypersensitivity to alendronate or other bisphosphonates

• esophageal abnormality

• inability to sit/stand upright for 30 minutes

• creatinine clearance less than 35 milliliters/minute

• hypothyroidism

• malignancy

• pregnancy

• prolonged steroid use